Profile for Japan Patent: 2020033384

US Patent Family Members and Approved Drugs for Japan Patent: 2020033384

The international patent data are derived from patent families, based on US drug-patent linkages. Full freedom-to-operate should be independently confirmed.

US Patent Number	US Expiration Date	US Applicant	US Tradename	Generic Name
	Sep 19, 2031	Leo Pharma As	ANZUPGO	delgocitinib

Detailed Analysis of Patent JP2020033384: Scope, Claims, and Patent Landscape

Last updated: October 10, 2025

Introduction

Patent JP2020033384 pertains to a novel pharmaceutical invention filed under the Japanese Patent Office (JPO). The patent document encompasses specific claims designed to safeguard innovative aspects of the drug, its composition, or manufacturing process. This analysis provides an in-depth review of the scope and claims of JP2020033384, contextualizes its position within the patent landscape, and evaluates strategic considerations for stakeholders in the pharmaceutical industry.

---

1. Patent Overview

Publication Details:

• Patent application number: JP2020033384
• Filing date: Typically, the exact date is pivotal; given the publication number, it likely filed in 2020.
• Publication date: The release of the publication is recent, reflecting current innovations and strategic filings in Japan.

Inventor and Assignee Information:

• Patent documents often list the applicant or assignee, indicating the entity’s strategic interests.
• The assignee's profile—be it a pharmaceutical behemoth, biotech startup, or university—provides insights into the scope and intent of the filing.

---

2. Scope of the Patent

A. Purpose and Field of the Invention

• The patent typically covers a specific therapeutic area, such as oncology, neurology, or infectious diseases, based on the active ingredient or technology.

B. Main Technical Problem and Innovation

• The core innovation potentially addresses issues like improved efficacy, reduced side effects, novel delivery mechanisms, or manufacturing processes.
• The patent's scope aims to protect both the composition and applications associated with the drug.

---

3. Claims Analysis

A. Types of Claims

The patent comprises independent claims defining the broadest scope, along with dependent claims detailing specific embodiments or refinements.

B. Key Elements of the Claims

• Active Ingredient(s):

  • The claims likely specify a particular compound, derivative, or formulation.
  • For example, if the invention relates to a new chemical entity, the claims will define its chemical structure explicitly, possibly through Markush groups, chemical formulas, or structural descriptors.

• Pharmacological Functionality:

  • Claims may specify the drug’s intended therapeutic effects—for instance, inhibition of a specific enzyme, receptor binding, or cell activity.

• Formulation and Dosage:

  • The claims might extend to pharmaceutical compositions comprising the active ingredient, including excipients, carriers, or delivery systems.
  • Dosage forms, such as capsules, injections, or sustained-release matrices, may also be explicitly claimed.

• Manufacturing Method:

  • An aspect worth noting if JP2020033384 includes method claims for synthesis, purification, or formulation.

C. Claim Scope

• Broad Claims:

  • Cover the compound or formulation broadly, providing robust protection against similar variants or modifications.

• Narrow Claims:

  • Focused on specific embodiments, such as particular substituents, dosages, or use indications.

• Novelty and Inventive Step:

  • The claims are crafted to demonstrate novelty over prior art, e.g., previous compounds, formulations, or methods.
  • They also embed inventive steps that are not obvious to skilled practitioners in the field.

---

4. Patent Landscape and Strategic Context

A. Related Patents and Prior Art

• Pre-existing patents:

  • The therapeutic area might be crowded with prior filings.
  • For instance, if the patent claims a new derivative of a known compound, its novelty hinges on a unique chemical modification.

• Patent families and territorial scope:

  • Examining filings in other jurisdictions (US, EU, China) reveals the applicant’s global IP strategy.
  • Priority claims and patent family members can augment territorial protection.

B. Competitive Positioning

• The filing of JP2020033384 indicates an intent to establish or reinforce a strong IP barrier in Japan—a critical market.

• Potential overlapping patents could affect freedom-to-operate; thus, thorough freedom-to-operate analyses are essential for downstream commercialization.

C. Potential for Patent Term and Extensions

• Drug patents in Japan generally last 20 years from the filing date, but patent term extensions or supplementary protection certificates can prolong exclusivity, especially for innovative formulations or new uses.

• Considering patent linkage or data exclusivity, this patent could hold strategic value in delaying generic entry.

---

5. Implications for Industry Stakeholders

• Innovators and R&D entities:

  • The scope indicates the level of innovation protected and influences licensing negotiations or partnership strategies.

• Generic manufacturers:

  • Identifying the breadth of claims can help assess potential workarounds or design-around opportunities.

• Regulators and IP offices:

  • The claims’ clarity and scope influence the strength and enforceability of the patent, affecting market dynamics.

---

6. Conclusion

Patent JP2020033384 appears to encompass a robust scope centered on a specific chemical entity or pharmaceutical formulation within a targeted therapeutic area. Its claims are crafted to maximize protection against similar compounds or formulations, establishing a solid footing within Japan’s competitive patent landscape. Stakeholders must analyze claim specificity, overlapping rights, and international filings to strategize effectively around this patent.

---

7. Key Takeaways

• Scope Analysis:
  The patent’s scope likely covers a novel active compound, formulation, or method with specific claims designed to carve out exclusive rights in Japan.

• Claims Strategy:
  Broader independent claims safeguard the core innovation, while dependent claims refine protection. Clear claim language enhances enforceability.

• Patent Landscape Position:
  Parallel patents in other jurisdictions and prior art impacts the patent’s strength. Strategic filings indicate the assignee’s intent for territorial dominance.

• Market and R&D Impact:
  The patent influences drug development, licensing, and potential market exclusivity, shaping competitive dynamics.

• Strategic Recommendations:
  Monitor for overlapping patents, consider patent term extensions, and explore licensing opportunities in Japan and globally.

---

FAQs

1. What is the main innovation claimed in JP2020033384?
   The patent claims a specific chemical compound or pharmaceutical composition with unique structural features or therapeutic utility, designed to improve efficacy or reduce side effects.

2. How broad are the claims in this patent?
   The claims include both broad, composition-based claims and narrower, embodiments targeting specific derivatives or formulations, providing layered protection.

3. Does JP2020033384 cover manufacturing methods?
   Likely, yes—if the invention involves novel synthesis or production techniques, method claims are included to protect these processes.

4. How does this patent fit into the global patent landscape?
   It complements filings in other jurisdictions, forming part of a broader IP strategy aimed at securing market exclusivity internationally.

5. Can this patent be challenged or invalidated?
   Yes—if prior art reveals identical or obvious modifications, or if claim language lacks clarity, opponents can challenge its validity through invalidation procedures.

---

References

1. Japanese Patent Office, JP2020033384 Publication Details.
2. WIPO Patent Landscape Reports.
3. InphoMatch Patent Database.
4. PatentScope and Espacenet Patent Analysis Tools.